anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder. A nano-cosmetic formulation, comprising a cosmetic includes the nanoformulation, wherein the modified chitosan polymer encapsulates the at least one vitamin D derivative, and wherein the at least one vitamin D derivative encompasses 0.1 to 20.0 wt % of the nano-cosmetic formulation's total weight.
Myeloid-derived suppressor cells (MDSCs) are a phenotypically heterogenous group of cells that potently suppress the immune response. A growing body of evidence supports the important role of MDSCs in a variety of lung diseases, such as asthma. However, the role of MDSCs in asthma exacerbation has so far not been investigated. Here, we studied the role of MDSCs in a murine model of influenza virus-induced asthma exacerbation. BALB/c mice were exposed to house dust mite (HDM) three times a week for a total of five weeks to induce a chronic asthmatic phenotype, which was exacerbated by additional exposure to the A/Hamburg/5/2009 hemagglutinin 1 neuraminidase 1 (H1N1) influenza virus. Induction of lung inflammatory features, production of T helper (Th) 1- and Th2- associated inflammatory cytokines in the lavage fluid and an increased airway hyper-responsiveness were observed, establishing the asthma exacerbation model. The number and activity of pulmonary M-MDSCs increased in exacerbated asthmatic mice compared to non-exacerbated asthmatic mice. Furthermore, depletion of MDSCs aggravated airway hyper-responsiveness in exacerbated asthmatic mice. These findings further denote the role of MDSCs in asthma and provide some of the first evidence supporting a potential important role of MDSCs in asthma exacerbation.
The invention provides a strain. The strain is a Lactobacillus crispatus strain, and the preservation number of the strain is CGMCC No.6364. The invention also provides a use of the strain in the preparation of colpitis prevention and/or treatment drugs, a use of the strain in the preparation of vagina nursing articles, and a use of the strain in the preparation of external genitals health articles. By adopting the above technical scheme, the strain can effectively realize an antagonistic effect on a plurality of pathogenic bacteria. The strain has a high adherence ability to vaginal epithelial cell. The strain can well meet practical clinic application demands.
PROBLEM TO BE SOLVED: To obtain a disintegrating tablet in oral cavity showing a good disintegrating property in the oral cavity, and having a sufficient strength, and to provide a method for producing the large amount of the above tablet simply by not using a special equipment. SOLUTION: This method for producing a disintegrating tablet in oral cavity, comprises the following processes (a), (b) and (c), and blending a medicine before a granulation or before a tablet formation. (a) a process for dissolving at least one kind of a saccharide having a high solubility to water (e.g.; xylitol), and at least one kind of a water soluble binder (e.g.; a polyvinylpyrrolidone), (b) a process for mixing at least one kind of an excipient (e.g.; mannitol), granulating, drying and then tabletting under a low compression, and (c) a process for aging tablets obtained by the above process (b).
This is a prospective cohort study consisting of a one-time visit by diabetic patients with optional following liver biopsy. The aim of the study is to evaluate whether liver fat fraction and liver stiffness, as determined by magnetic resonance imaging, are associated with subclinical cardiovascular disease, as evaluated by coronary artery calcium scan in diabetics. During the visit, patients will undergo review of medical history, vitals (including body mass index, blood pressure), physical exam, blood work, urine collection, ECG, magnetic resonance imaging (MRI), including MR proton density fat fraction (MRI-PDFF) and MR elastography, ultrasound using acoustic radiation force impulse (ARFI) imaging, and computed tomography (CT) scan for coronary artery calcium scoring. Blood work will be sent for labs relevant to traits of metabolic syndrome including markers for diabetes (hemoglobin A1C, fasting glucose) and hyperlipidemia (lipid panel). Serum, plasma and whole blood will be stored for future studies. Results from history, physical exam, and radiographic imaging will be analyzed and if they indicate the presence of nonalcoholic steatohepatitis, patients will be offered an optional liver biopsy for further assessment. All patients will be invited to continue in the study and have follow-up visits every two years for a total duration of the study of 5 years.
The prospective, single-arm, multi-center clinical trial is to evaluate whether the endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System can achieve the safety and effectivenessof liver cancer ablation treatment. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. This clinical trial requires 69 subjects. Qualified participants will receive EUS-guided LA by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary outcome (the complete ablation (CA) rate and the effective rate of EUS-guided LA by LaserPro Diode Laser System for liver cancer) and secondary outcomes (technical success rate, major complication rate, partial response rate, secondary ablation rate, progression-free survival (PFS), overall survival rate (OS), local tumor progression (LTP), distant tumor recurrence (DTR), quality of life score and alpha-fetoprotein levels). The one-month follow-up after the operation, three-phase MRI, liver function and tumor markers were reviewed monthly to observe the lesion necrosis and tumor marker changes. After that, tumor markers, three-phase MRI of liver were examined every 2 to 3 months. After then, statistical comparisons of safety and effectivenessof the producedure will be made according to groups.
The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases,gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as  Clostridium difficile,Clostridium perfingens ,  Fusobacterium nucleatum , and an enterotoxigenic strain of  Bacteroides fragilis . Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species.Both types of compounds, especially the ones with narrow-spectrum antibacterialactivity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.
AIMS: This study endeavors to explore the ramifications of early dynamic blood glucose (BG) trajectories within the initial 48 h of intensive care unit (ICU) admission on mortality among critically ill heart failure (HF) patients.
METHODS: The study employed a retrospective observational design, analyzing dynamic BG data of HF patients from the Medical Information Mart for Intensive Care IV database. The BG trajectory subphenotypes were identified using the hierarchical clustering based on the dynamic time-warping algorithm. The primary outcome of the study was 28-day mortality, with secondary outcomes including 180-day and 1-year mortality.
RESULTS: We screened a total of 21,098 HF patients and finally 15,092 patients were included in the study. Our results identified three distinct BG trajectory subphenotypes: increasing (n = 3503), stabilizing (n = 6250), and decreasing (n = 5339). The increasing subphenotype was associated with the highest mortality risk at 28 days, 180 days, and 1 year. The stabilizing and decreasing subphenotypes showed significantly lower mortality risks across all time points, with hazard ratios ranging from 0.85 to 0.88 (P<0.05 for all). Sensitivity analyses confirmed the robustness of these findings after adjusting for various covariates.
CONCLUSIONS: Increasing BG trajectory within 48 h of admission is significantly associated with higher mortality in patients with HF. It is necessary to devote greater attention to the early BG dynamic changes in HF patients to optimize clinical BG management and enhance patient prognosis.
PURPOSE: To obtain a therapeutic agent for a digestive system cancer comprising a malformin as an active ingredient. CONSTITUTION: This therapeutic agent for a digestive system cancer contains 0.01-100wt.% of at least one malformin among physiologically active substance malformins as an active ingredient. Malformins have inhibitory action on multiplication of various digestive system cancer cells, relatively low toxicity and are effective for treating stomach cancer, esophagus cancer, pancreatic cancer, especially hepatoma and colon cancer. A dose is 1-100mg/kg/day in the case of parenteral administration and 5-500mg/kg/day in the case of oral administration. Malformins are obtained by culturing Aspergillus sp. NFO 2525 strain (FERM P-14,557) in a nutritive medium.
Renal impairment can significantly alter the disposition of tolterodine immediate release and its metabolites. In a study conducted in patients with creatinine clearance between 10 and 30 mL/min, tolterodine and 5-HMT levels were approximately 2 to 3 fold higher in patients with renal impairment than in healthy volunteers. Exposure levels of other metabolites of tolterodine (e.g., tolterodine acid, N-dealkylated tolterodine acid, N-dealkylated tolterodine, and N-dealkylated hydroxy tolterodine) were significantly higher (10 to 30 fold) in renally impaired patients as compared to the healthy volunteers. The recommended dose for patients with severe renal impairment (CCr: 10 to 30 mL/min) is tolterodine tartrate extended-release capsules, 2 mg daily. Patients with CCr<10 mL/min have not been studied and use of tolterodine tartrate extended-release capsules in this population is not recommended [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.6)]. Tolterodine tartrate extended-release capsules have not been studied in patients with mild to moderate renal impairment [CCr 30 to 80 mL/min].
A method, system, and computer program product to prevent misinterpretation of communications via artificial intelligence assistants. The method includes monitoring an artificial intelligence enabled communication. The method also includes analyzing messages, participants, and actions within the communication. The method also includes identifying critical data within the communication. The method also includes determining critical sequence data, where the critical sequence data is a sequence of conversation elements that contains the critical data. The method also includes predicting an uncertainty level for the critical sequence data, where the uncertainty level indicates an amount of uncertainty that the artificial intelligence correctly interprets the critical sequence data. The method also includes determining that the uncertainty level for the critical sequence data is above a threshold uncertainty value, resulting in critical sequence data that is subject to misinterpretation. The method also includes resolving any uncertainties for the critical sequence data.
Infants and toddlers (ITs) with hemophilia have unique bleeding features. Factor prophylaxis has been shown to decrease the risk of intracranial hemorrhage (ICH), which supports recommendations to begin at a young age. Clinical and demographic characteristics were analyzed for 883 ITs ≤2 years old with hemophilia A and B, seen at US Hemophilia Treatment Centers and enrolled in the Community Counts Registry, a surveillance program of the Centers for Disease Control and Prevention. ICH in the first 2 years of life was seen in 68 of 883 (7.7%) ITs, of whom 8 of 68 (11.8%) were on continuous prophylaxis at the time of ICH. ITs in this study usually started prophylaxis within the first year of life (mean, 10.3 months), with earlier ages of prophylaxis initiation in later birth cohorts in ITs with hemophilia A. Compared with those without a family history (FH) of hemophilia, known positive FH of hemophilia was associated with earlier age of diagnosis (P ≤ .0001) and decreased rates of vaginal delivery (P = .0006). The use of factor VIII mimetics and extended half-life clotting factor prophylaxis increased with later birth cohorts for ITs with hemophilia A and B. The study highlights that ICH rates in ITs with hemophilia remains substantial and underscores the need for further research to identify modifiable risk factors to prevent ICH by earlier diagnosis and initiating prophylaxis early, even within the first month of life.
The face-beautifying medicated mask capable of treating facial dermopathies of facial acne and chloasma, etc. mainly is composed of a specially-made mask, a medicated bag and 18 Chinese herbal medicines of lonicera flower, etc. placed in the medicated bag. ADVANTAGE-. Said product has the functions of promoting blood circulation to remove blood stasis and spots, and removing pathogenic heat from the blood and toxic material from the body. Its total effective rate is up to 94.3%.
Rickettsial diseases cover a broad spectrum of illnesses. Scrub typhus is present worldwide, and Orientia tsutsugamushi is the causative agent of this chigger mite-borne infectious illness. Infections exhibit a range of severity, from mild illness to the more severe manifestation of multiorgan failure. We report three cases of scrub fever (55-year-old female, 63-year-old female, and 29-year-old male), all cases developed focal or pan-digital gangrene. All cases were successfully treated by administering doxycycline and additional supportive measures. Digital gangrene is uncommon in scrub typhus. Clinical suspension for early diagnosis and appropriate treatment may avoid further complications.
The first dose of either oral or IV ibuprofen will be given at the time the patient is randomized.The subsequent doses of indometacin or ibuprofen are also determined according to the echocardiographic PDA flow patterns at intervals of once every 24 hours from the last dose. The dosage of both oral ibuprofen (Ibuprofen suspension, 20 mg/ml, Yung Shing Co., Taiwan) and IV ibuprofen (PedeaR 20 mg/ml, developed by Orphan Europe and approved by the EMEA) are an initial dose of 10 mg/kg and then 5 mg/kg at 24-hour intervals as indicated by PDA flow pattern.
Methods are disclosed which may be used for the production of antibodies, or antibody fragments, which have the same binding specificity as a parent antibody but which have increased human characteristics. Humanised antibodies may be obtained by chain shuffling, perhaps using phage display technology. In one embodiment, a polypeptide comprising a heavy or light chain variable domain of a non-human antibody specific for an antigen of interest is combined with a repertoire of human complementary (light or heavy) chain variable domains. Hybrid pairings which are specific for the antigen of interest are selected. Human chains from the selected pairings may then be combined with a repertoire of human complementary variable domains (heavy or light) and humanised antibody polypeptide dimers can then be selected for binding specificity for antigen. The methods may be combined with CDR-imprinting. In another embodiment, component part of an antigen-binding site of a non-human antibody known to bind a particular antigen is combined with a repertoire of component parts of an antigen-binding site of human antibody, forming a library of antibody polypeptide dimers with antigen-binding sites. Hybrids selected from this library may be used in a second humanising shuffling step, or may already be of sufficient human character to be of value, perhaps after some modification to increase human character still further.
PURPOSE: To obtain a vaccine using a bronchial septicemic bacterial antigen, and useful for preventing cat's upper respiratory diseases. CONSTITUTION: This vaccine is produced using a bronchial septicemic bacterial antigen (e.g. fimbriae, bacterin, attenuated bacteria). Specifically, this vaccine is obtained by introducing bronchial septicemic bacterial cells into an appropriate culture medium to culture the cells at 36-38 deg.C followed by, as necessary, concentrating the cells by mechanical treatment. This vaccine may also contain at least one kind of antigen selected from cat's herpes viral antigens, cat's Caliciviral antigens, psittacosis chlamydial antigen and cat-infectious enteritis viral antigens. This vaccine is administered by such means as intramuscular injection, subcutaneous injection, intranasal cavity administration, or intraoral, intraocular or intratracheal administration. This vaccine contains 10<2> to 10<10> cells or 1-500μg antigen per dose.
PURPOSE: To prepare a cosmetic composition for makeup having a high content of a silicone wax without requiring the addition of a surfactant by dispersing the silicone wax into an aqueous phase containing two types of water-soluble acrylic polymers. CONSTITUTION: This stable dispersion of a silicone wax containing >=10 wt.% of a silicone wax is prepared in an aqueous phase by using two types of acrylic polymers. The first acrylic polymer comprises at least one copolymer of a 3-6C single double bond-containing acid or its acid anhydride and a long-chain acrylic ester and the other polymer comprises at least one homopolymer of acrylic acid or its salt or a copolymer thereof (except a copolymer of acrylic acid and a long-chain acrylic ester and its salt). The dispersion contains up to 60 wt.% of the silicone wax. The composition is used for a cosmetic composition and suitable for, e.g. a foundation, an eye shadow or a rouge.
FIELD: medicine, diagnostic ultrasonic tomography. SUBSTANCE: contrasting substance is a biocompatible emulsion of type "oil-in-water". Oily phase has an oil-soluble substance in a gaseous form at normal human body temperature, volatile organic liquid at boiling point above indicated one but not above 60 C, or a substance able to regenerate gas. Method of preparing a contrasting substance involves emulsification of an oily phase containing the above indicated substances, at least, in a single lipophilic solvent, in an aqueous phase. Method can be realized by addition of an oil-soluble substance in an oily phase of preliminary prepared emulsion of type "oil-in-water". Method of producing human or animal body image involves administration of new contrasting substance in body and producing an ultrasonic image. EFFECT: enhanced efficiency. 15 cl, 14 ex
FIELD: medicine, biochemistry. SUBSTANCE: method involves extraction, purification and drying the end product. Native sapropel is used as raw without any preliminary treatment. Sapropel is infused and extract is prepared using three-fold volume of 0.05 M ammonium solution. Extract is concentrated by evaporation by 80-100-fold, exposed at -15 C for 24 h, insoluble particles were removed by centrifugation at 3000-4000g followed by dialysis through cellophane T-100 against 200-fold distilled water volume. Nondialyzed fraction is evaporated to dryness and the end product is obtained as light-brown, good water-soluble powder. The end product is anticoagulating agent, its activity is 95 ± 3 U (EA)/1 mg dry matter. The yield of product is 8000-10000 EA/kg sapropel. EFFECT: improved method of preparing, increased yield.
Central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) carries a dismal prognosis and most clinical guidelines recommend CNS prophylaxis to patients deemed at high risk of CNS relapse. However, results from observational studies investigating the effect of CNS prophylaxis have yielded conflicting results. The aims of this study were to evaluate: (i) whether addition of prophylactic intravenous high-dose methotrexate (HD-MTX) reduces the risk of CNS relapse in high-risk DLBCL patients treated with R-CHOP or similar, and (ii) whether HD-MTX prophylaxis confers an overall survival benefit, irrespective of CNS relapse. We performed a systematic search of MEDLINE/PubMed and EMBASE for data on DLBCL patients at high risk of CNS relapse treated with R-CHOP or similar who received HD-MTX as an intervention and a comparator arm of patients who did not receive prophylaxis and/or intrathecal prophylaxis. A risk of bias was estimated using the ROBINS-I tool and the quality of the evidence was assessed by the GRADE approach. Finally, a meta- analysis based on the systematic review was conducted. A total of 1,812 studies were screened. No randomized controlled trials were identified. Seven observational studies comprising 1,661 patients met the inclusion criteria. We found a statistically non-significant relative risk of 0.54 (95% confidence interval: 0.27-1.07) of CNS relapse for patients receiving HD-MTX versus controls. The meta-analysis investigating mortality demonstrated a relative risk of death of 0.70 (95% confidence interval: 0.44-1.11) for patients treated with HD-MTX versus controls. The overall risk of bias was adjudged as "serious" and the quality of the evidence was rated as "low". In conclusion, our data indicate that HD-MTX does not prevent or, at best, only slightly reduces the risk of CNS relapse and confers no survival benefit.
<P>PROBLEM TO BE SOLVED: To provide sebum-absorbing paper containing thermostable microcapsules.  <P>SOLUTION: This sebum-absorbing paper contains, on at least one surface of the paper or more preferably on only one surface of the paper, microcapsules which include at least one crystalline compound having an enthalpy of melting (ΔHf) of 75-330 kJ/kg measured with a differential scanning calorimeter. This invention is further directed toward a manufacturing method for the sebum- absorbing paper and also a use of the sebum-absorbing paper to contribute to a long-acting refreshing effect on the skin. In order to give the refreshing effect on the skin, the melting temperature of the crystalline compound encapsulated within the microcapsules has to be slightly lower than the temperature of the human skin. The crystalline compound is preferably manufactured from an encapsulated compound having a melting temperature at approximately 25-40°C.  <P>COPYRIGHT: (C)2003,JPO